Barts Cancer Institute (Queen Mary University of London)

About Barts Cancer Institute

Barts Cancer Institute (BCI), part of Queen Mary University of London, is a leading research institution dedicated to understanding and treating cancer. Established in 2001, BCI has rapidly become a hub for innovative cancer research, focusing on translating scientific discoveries into effective therapies.

The institute is home to a diverse team of researchers, clinicians, and support staff who work collaboratively to advance the field of oncology. BCI’s core activities include basic, translational, and clinical research, with a strong emphasis on personalised medicine.

• Research Excellence: BCI is renowned for its cutting-edge research in various cancer types, including breast, prostate, and blood cancers.
• Clinical Trials: The institute actively conducts clinical trials, providing patients access to the latest treatments and therapies.
• Education and Training: BCI is committed to educating the next generation of cancer researchers and healthcare professionals through comprehensive training programmes.

With state-of-the-art facilities and a collaborative environment, BCI fosters innovation and discovery. The institute’s vision is to improve patient outcomes through research that bridges the gap between laboratory findings and clinical application.

BCI also engages with the community, raising awareness about cancer prevention and treatment options. By partnering with other institutions and organisations, BCI aims to enhance cancer care and research on a global scale.

In summary, Barts Cancer Institute stands at the forefront of cancer research, driven by a mission to eradicate cancer and improve the lives of those affected by this disease.